跳至主要内容
临床试验/NCT01695447
NCT01695447Unknown不适用

Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy

TingBo Liang1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2012年1月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
1
主要终点
pancreatic fistula

研究概览

简要总结

The purpose of this study is to determine whether duct-to-mucosa is better than invagination in pancreaticojejunostomy after pancreaticoduodenectomy. This single-centre, open, randomized controlled trail is conducted following ISGPF criteria for pancreatic fistula (PF). The duration of the study is supposed to start from Jan 5th 2012 and last to Dec 2014, until 100 or more cases are accessible. Patients diagnosed with pancreatic cancer, peri-ampullar carcinoma or other benign or malignant diseases which need to operate pancreaticoduodenectomy will be included. Main outcomes are pancreatic fistula rate, mortality, morbidity, reoperation and hospital stay. The investigators assumption that duct-to-mucosa is better than invagination.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with pancreatic cancer or other diseases which need pancreaticoduodenectomy and pancreaticojejunostomy
  • 18 to 80 y/o
  • Operation-tolerated
  • Informed consent

排除标准

  • History of gastrointestinal operation
  • Pancreaticoduodenectomy is given up during operation
  • Pancreatic duct is difficult to locate
  • Patients require to exit from the study anytime

结局指标

主要结局

pancreatic fistula

时间窗: From date of operation until the date of dischage or date of death from any cause, whichever came first,, assessed up to 200 days

The determine of pancreatic fistula follows the International Study Group on Pancreatic Fistulas (ISGPF) criteria.

次要结局

  • Mortality(From date of operation until the date of in-hospital death or death within 30 days after operation, whichever came first, assessed up to 200 days)
  • Morbidity(From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days)
  • Reoperation(From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days)
  • Hospital stay(From date of operation until the date of discharge or date of death from any cause, whichever came first, assessed up to 200 days)

研究者

发起方
TingBo Liang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

TingBo Liang

The Second Affiliated Hospital, School of Medicine, Zhejiang Universtiy

Zhejiang University

研究点 (1)

Loading locations...

相似试验